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Background: Historically, hepatopancreatobiliary surgeons and gastroenterologists have undertaken
endoscopic retrograde cholangiopancreatography (ERCP) using benzodiazepine sedation (BS). This is
poorly tolerated by a substantial number of patients, which leads to its potential premature abandonment
and subsequent additional investigations and therapeutics, and hence to the exposure of patients to
avoidable risk and the health service to increased costs. Furthermore, concerns have been raised in the
recent literature regarding safe sedation techniques.
Objectives: The aim of this study was to compare the completion rates and safety profile of ERCP using
BS vs. those of ERCP using light propofol anaesthesia (PA).
Methods: We carried out a retrospective, case-matched comparison analysis of consecutive patients
who underwent ERCP with BS vs. PA, in the presence of an anaesthetist, over a 2-year period.
Benzodiazepine sedation consisted of midazolam, fentanyl and buscopan. Propofol anaesthesia con-
sisted of propofol, fentanyl and buscopan administered via a mouth guard in a non-intubated patient.
Patient demographics, complications and completion rates were recorded. Procedural monitoring
included pulse oximetry, non-invasive blood pressure, electrocardiography and end-tidal CO2. Statistical
analyses used t-tests to compare continuous variables and chi-squared and Fisher's exact tests to
compare categorical variables. A P-value of <0.05 was considered significant.
Results: Of 252 patients included in the study, 128 (50.8%) received BS and 124 (49.2%) received PA.
Median ages in the BS and PA groups were 69 years (range: 20–99 years) and 65 years (range: 26–98
years), respectively (P = 0.07). Median hospital stays in the BS and PA groups were 1 day (range: day case
to 61 days) and 1 day (range: day case to 38 days), respectively (P = 0.61). Incidences of mild
anaesthesia-related complications in the BS and PA groups were 2.3% and 2.4%, respectively (P = 0.97).
There were no severe anaesthesia-related complications. Incidences of mild procedural complications in
the BS and PA groups were 2.3% and 1.6%, respectively (P = 0.68). One severe procedural complication
occurred in the PA group. Incidences of incomplete ERCP procedures in the BS and PA groups were
10.9% (n = 14) and 4.0% (n = 5), respectively (odds ratio = 2.92, 95% confidence interval 1.02–8.38;
chi-squared test, P = 0.04; Fisher's exact test, P = 0.03).
Conclusions: Propofol anaesthesia for ERCP carried out in the presence of an anaesthetist is safe and
may improve procedural completion rates.
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Introduction
Endoscopic retrograde cholangiopancreatography (ERCP) is an
important diagnostic and interventional tool in biliary and pan-
creatic disease. Historically, clinicians have undertaken ERCP
under benzodiazepine sedation (BS).1,2 However, this is often
poorly tolerated. Premature abandonment brought about by
patient intolerance of ERCP necessitates repeat attempts or
further interventions, including percutaneous transhepatic
cholangiography (PTC). This causes patients to be exposed to
potentially avoidable risks and represents increased costs to the
health service.
Recently, clinicians have considered the use of propofol anaes-
thesia (PA), either in conjunction with or in place of BS for
advanced endoscopic procedures.1–4 However, the potential anaes-
thetic risks associated with an open shared airway have proved a
stumbling block that has prevented PA in ERCP from becoming a
standard of care.
In our institution, it was felt that patients tolerated PA better
than BS during ERCP. Consequently, in 2005 local practice
changed and PA became the standard of care. This study was
designed to compare the safety and completion rates of ERCP
conducted under PA vs. those of ERCP performed using BS in 252
patients.
Materials and methods
This paper reports a retrospective, case-matched comparison
analysis of patients who underwent ERCP with either PA or BS.
Consecutive patients who underwent ERCP with BS (n = 128)
over a 1-year period prior to 2005 were identified and compared
with a matched group of consecutive patients who underwent
ERCP with PA (n = 124) over a 1-year period after 2005.
All ERCP procedures were undertaken by a senior endoscopist
with over 20 years of experience (IMP). Each patient was entered
in the study once. Procedural monitoring included pulse oxim-
etry, non-invasive blood pressure, electrocardiography and end-
tidal carbon dioxide (CO2).
Benzodiazepine sedation was administered by the clinician
performing the ERCP without an anaesthetist being present. The
sedation consisted of midazolam, fentanyl citrate at a dose of
1.0–1.5 mg/kg and 20 mg of buscopan, which was increased if
peristalsis returned.
Propofol anaesthesia was undertaken by a consultant anaesthe-
tist or, in special circumstances, a senior trainee with experience in
anaesthesia in this environment. The PA consisted of total i.v.
anaesthesia with propofol running at 2–9 mg/ml blood concentra-
tion, usually running at 4 mg/ml after the loading dose. Prior to
induction, the patient was given 0.5–1.5 mg/kg of fentanyl citrate,
according to his or her age and ASA (American Society of Anes-
thesiologists) status. This was followed by 20 mg of buscopan,
which was increased if peristalsis returned. The airway was kept
clear using a purpose-made mouth guard in a non-intubated
patient. End-tidal CO2 was monitored via the mouth guard to
comply with the Royal College of Anaesthetists guidelines for
anaesthesia.
Patient demographics were recorded. The primary endpoint
was procedure completion. An incomplete procedure was defined
as abandonment or altered intervention (e.g. stent rather
than extraction of gallstones within the common bile duct)
brought about by patient discomfort or abnormalities detected
by monitoring.
Anaesthetic and procedural complications were recorded.
Complication severity was determined according to the scale
described by Dindo et al.5 Periprocedural mortality was defined as
death during hospital admission or within 30 days of ERCP.
Statistical analyses were conducted using t-tests to compare
continuous variables and chi-squared and Fisher’s exact tests to
compare categorical variables. A P-value of <0.05 was considered
significant.
Results
Of the 252 patients who underwent ERCP, 128 (50.8%) and 124
(49.2%) received BS and PA, respectively. Median ages in the BS
and PA groups were 69 years (range: 20–99 years) and 65 years
(range: 26–98 years), respectively (P = 0.07). Median hospital stays
in the BS and PA groups were 1 day (range: day case to 61 days)
and 1 day (range: day case to 38 days), respectively (P = 0.61). The
PA group included 22, 73, 21, two and six patients with ASA scores
of 1, 2, 3, 4 and unrecorded, respectively. ASA was not routinely
recorded in the BS group.
Table 1 demonstrates the indications for ERCP in both groups.
The ‘other cancers’ group consisted of metastatic gastric adeno-
carcinoma (n = 1), metastatic gallbladder cancer (n = 2), duodenal
cancer (n = 1), metastatic renal cell carcinoma (n = 1) and meta-
static cancer of undetermined origin (n = 1).
Incidences of incomplete ERCP procedures in the BS and PA
groups were 10.9% (n = 14) and 4.0% (n = 5), respectively (odds
ratio [OR] = 2.92, 95% confidence interval [CI] 1.02–8.38; chi-
squared test, P = 0.04; Fisher’s exact test, P = 0.03).
Table 2 shows the morbidity and mortality associated with
ERCP. Anaesthesia-related complications included hypotension
(n = 1) and prolonged recovery (n = 2) in the BS group, and
hypotension (n = 1) and tachycardia (n = 2) in the PA group. There
were no severe anaesthesia-related complications in either group.
Procedural complications included fever (n = 1), bleeding (n =
1) and mild pancreatitis (n = 1) in the BS group, and fever (n = 2)
and severe pancreatitis (n = 1) in the PA group.
One patient in the PA group died within 30 days of ERCP
following severe pancreatitis secondary to ERCP. There were no
periprocedural deaths in the BS group (chi-squared test, P = 0.31).
Discussion
It is crucial that sedation is safe and effective during ERCP. In
reality, the minimizing of patient movement while maintaining
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safe sedation using BS can be difficult to achieve.6 Increased move-
ment and discomfort during an ERCP intervention may increase
the risk for procedural complications.
The advent of endoscopic ultrasound and magnetic resonance
cholangiopancreatography has changed the focus of ERCP from
that of a diagnostic procedure to one of an intervention.7 In the
current study, the significant increase in the number of patients
with pancreatic cancer who underwent ERCP under PA compared
with BS is evidence in support of this.
Similarly, the co-morbidities of patients who require ERCP
have changed.7 One study showed that 46% of patients undergo-
ing ERCP had an ASA status of 3.7 Hence, the maintenance of
safe sedation for longer procedures has become more difficult in
accordance with both the increased complexity of the procedures
and reduced patient tolerance. The reluctance to use PA rather
than BS results from difficulties in monitoring patient respiration
and the increased costs inherent in the presence of a dedicated
anaesthetist. We have overcome the former problem by developing
a simple and easy method of monitoring end-tidal CO2, which is
considered the standard internationally.8
This study showed no difference between ERCP procedures
carried out under PA and those performed under BS in terms of
procedural or anaesthesia-related complications. There was also
no difference in length of hospital stay between the two groups.
Wehrmann and Riphaus described a total incidence of adverse
anaesthetic events of 1.4% in a retrospective study of 9547 ERCP
procedures performed under PA.9 These included assisted venti-
lation (0.4%), endotracheal intubation (0.09%), intensive care
monitoring (0.3%) and death (0.03%).9 The mortality quoted,
however, was not conclusively attributed to propofol sedation.
Furthermore, as this was not a comparative analysis, it is difficult
to conclude any significant difference in rates of anaesthesia-
related complications between PA and BS.
Patients who require ERCP may have cholangitis, hepatic dys-
function, pancreatic cancer, bile duct strictures, ascitis, pleural
effusions, or metabolic and clotting disturbances.7 These patients
are generally more unwell than those undergoing standard upper
gastrointestinal endoscopy. Therefore, the safety of ERCP depends
on the medical condition of the patient. It has been suggested that
all patients undergoing ERCP should be subject to a full pre-
procedural anaesthetic assessment and that an anaesthetist should
be present regardless of the method of sedation.7 This counters the
argument that PA would increase costs to the health service by
necessitating the presence of an anaesthetist.
A randomized controlled trial of PA compared with BS for
ERCP in 32 patients showed that PA was better tolerated, had
Table 1 Indications for endoscopic retrograde cholangiopancreatography (ERCP)
Indication Total, n (%) ERCP with BS, n (%) ERCP with
PA, n (%)
OR (95% CI) P-valuea P-valueb
Gallstone disease 175 (69.4) 91 (71.1) 84 (67.7) 1.17 (0.69–2.00) 0.33 0.33
Pancreatic carcinoma 27 (10.7) 6 (4.7) 21 (16.9) 0.24 (0.09–0.62) 0.002 0.001
Cholangiocarcinoma 3 (1.2) 0 3 (2.4) 1.03 (0.99–1.05) 0.08 0.12
Ampullary carcinoma 5 (2.0) 5 (3.9) 0 0.96 (0.93–0.99) 0.03 0.03
Other cancers 6 (2.4) 4 (3.1) 2 (1.6) 1.97 (0.35–10.90) 0.43 0.36
Primary sclerosing cholangitis 5 (2.0) 2 (1.6) 3 (2.4) 0.63 (0.11–3.90) 0.63 0.49
Benign stricture 21 (8.3) 15 (11.7) 6 (4.8) 2.60 (0.98–6.97) 0.049 0.04
Bile leak post-laparoscopic cholecystectomy 8 (3.2) 5 (3.9) 3 (2.4) 1.60 (0.38–7.01) 0.50 0.38
Anastomotic dilatation 2 (0.8) 0 2 (1.6) 1.02 (0.99–1.04) 0.15 0.24
aChi-squared test
bFisher's exact test
OR, odds ratio; 95% CI, 95% confidence interval
Table 2 Morbidity and mortality for endoscopic retrograde cholangiopancreatography (ERCP) under benzodiazepine sedation (BS) and
propofol anaesthesia (PA)
ERCP with BS, n (%) ERCP with PA, n (%) OR (95% CI) P-valuea P-valueb
Mild anaesthetic complications (<grade III)5 3 (2.3) 3 (2.4) 0.97 (0.19–4.9) 0.97 0.64
Severe anaesthetic complications (grade III)5 0 0 – – –
Mild procedural complications (<grade III)5 3 (2.3) 2 (1.6) 1.46 (0.24–8.9) 0.68 0.52
Severe procedural complications (grade III)5 0 1 (0.8) 1.0 (0.99–1.02) 0.31 0.49
Periprocedural death 0 1 (0.8) 1.0 (0.99–1.02) 0.31 0.49
aChi-squared test
bFisher's exact test
OR, odds ratio; 95% CI, 95% confidence interval
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fewer haemodynamic effects and required a shorter recovery
period.10 Furthermore, Kongkam et al. demonstrated no differ-
ence in the rate of adverse events between PA and BS.4 However,
these authors were unable to demonstrate a significant difference
in completion rates between the two groups; the latter finding,
which disagrees with results of the current study, may reflect the
underpowering of the study (n = 134).4
The significant improvement in the completion rate with PA,
seen in the current study, reflects increased patient tolerance and
reduced movement. In addition to its detrimental effects on ERCP
completion, there is evidence that increased patient movement
may raise the likelihood of procedural complications.11 One study
demonstrated a significant reduction in procedural morbidity in
ERCP conducted under general anaesthesia compared with under
conscious sedation.11 The current study may not have been suffi-
ciently powered to show this.
In conclusion, for ERCP, PA administered in the presence of an
anaesthetist may significantly improve completion rates without
increasing procedural and anaesthesia-related complications
compared with BS.
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